نتائج البحث - "Tannir, N."

1

دورية أكاديمية

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial

المؤلفون: Feils, A. S., Erbe, A. K., Birstler, J., Kim, K., Hoch, U., Currie, S. L., Nguyen, T., Yu, D., Siefker-Radtke, A. O., Tannir, N., Tolaney, S. M., Diab, A., Sondel, P. M.

المساهمون: Midwest Athletes Against Childhood Cancer, Stand Up To Cancer, St. Baldrick's Foundation, American Association for Cancer Research, University of Wisconsin Carbone Cancer Center, National Institutes of Health, Nektar Therapeutics

المصدر: Cancer Immunology, Immunotherapy ; volume 72, issue 7, page 2099-2111 ; ISSN 0340-7004 1432-0851

مصطلحات موضوعية: Cancer Research, Oncology, Immunology, Immunology and Allergy

الإتاحة: https://doi.org/10.1007/s00262-023-03383-wTest

View record in BASE

2

دورية أكاديمية

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

المؤلفون: Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R

المصدر: OncoTargets and Therapy, Vol Volume 14, Pp 3037-3049 (2021)

مصطلحات موضوعية: crizotinib, pazopanib, vegf, alk/ros1, met, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/a-phase-i-trial-of-the-metalkros1-inhibitor-crizotinib-combined-with-t-peer-reviewed-fulltext-article-OTTTest; https://doaj.org/toc/1178-6930Test

الوصول الحر: https://doaj.org/article/ecdd833273ef4a6b981967601c3b0917Test

View record in DOAJ

النص الكامل

3

دورية أكاديمية

LBA68 Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator’s choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09)

المؤلفون: Tannir, N., Formiga, M.N., Agarwal, N., Pal, S.K., Cho, D., George, D.J., Hong, W., Tang, L., Qureshi, A., Tagliaferri, M.A., Zalevsky, J., Penkov, K.D.

المصدر: Annals of Oncology ; volume 33, page S1433 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2022.08.073Test
https://api.elsevier.com/content/article/PII:S0923753422039515?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422039515?httpAccept=text/plainTest

View record in BASE

4

دورية أكاديمية

1461P Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era

المصدر: Annals of Oncology ; volume 33, page S1213-S1214 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2022.07.1564Test
https://api.elsevier.com/content/article/PII:S0923753422034159?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422034159?httpAccept=text/plainTest

View record in BASE

5

دورية أكاديمية

1459P Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC)

المؤلفون: Escudier, B., Motzer, R.J., Dyer, M., May, J.R., Ejzykowicz, F., Kurt, M., Lee, C-W., Wang, P., Testa, E., Sharpe, D.J., George, S., Tannir, N.

المصدر: Annals of Oncology ; volume 33, page S1212 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2022.07.1562Test
https://api.elsevier.com/content/article/PII:S0923753422034135?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422034135?httpAccept=text/plainTest

View record in BASE

6

دورية أكاديمية

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma

المؤلفون: Sternberg C. N., Motzer R. J., Hutson T. E., Choueiri T. K., Kollmannsberger C., Bjarnason G. A., Paul Nathan, Porta C., Grunwald V., Dezzani L., Han J., Tannir N. M.

المساهمون: Sternberg, C. N., Motzer, R. J., Hutson, T. E., Choueiri, T. K., Kollmannsberger, C., Bjarnason, G. A., Paul, Nathan, Porta, C., Grunwald, V., Dezzani, L., Han, J., Tannir, N. M.

مصطلحات موضوعية: First-line, Sunitinib, Tyrosine kinase inhibitor, VEGF, VEGFR, Carcinoma, Renal Cell, Drug Administration Schedule, Female, Human, Kidney Neoplasm, Logistic Model, Male, Pyrimidine, Random Allocation, Sulfonamide, Survival Analysi, Treatment Outcome

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31601514; info:eu-repo/semantics/altIdentifier/wos/WOS:000498697000020; volume:17; issue:6; firstpage:425; lastpage:435.e4; numberofpages:15; journal:CLINICAL GENITOURINARY CANCER; http://hdl.handle.net/11586/327478Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85073010303

الإتاحة: https://doi.org/10.1016/j.clgc.2019.01.015Test
http://hdl.handle.net/11586/327478Test

View record in BASE

7

دورية أكاديمية

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

المساهمون: Motzer, R. J., Rini, B. I., Mcdermott, D. F., Aren Frontera, O., Hammers, H. J., Carducci, M. A., Salman, P., Escudier, B., Beuselinck, B., Amin, A., Porta, C., George, S., Neiman, V., Bracarda, S., Tykodi, S. S., Barthelemy, P., Leibowitz-Amit, R., Plimack, E. R., Oosting, S. F., Redman, B., Melichar, B., Powles, T., Nathan, P., Oudard, S., Pook, D., Choueiri, T. K., Donskov, F., Grimm, M. -O., Gurney, H., Heng, D. Y. C., Kollmannsberger, C. K., Harrison, M. R., Tomita, Y., Duran, I., Grunwald, V., Mchenry, M. B., Mekan, S., Tannir, N. M.

مصطلحات موضوعية: Alanine Transaminase, Amylase, Antineoplastic Agent, Antineoplastic Combined Chemotherapy Protocol, Carcinoma, Renal Cell, Fatigue, Follow-Up Studie, Human, Hypertension, Intention to Treat Analysi, Ipilimumab, Kidney Neoplasm, Lipase, Nivolumab, Paresthesia, Progression-Free Survival, Sunitinib, Survival Rate

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31427204; info:eu-repo/semantics/altIdentifier/wos/WOS:000488267700039; volume:20; issue:10; firstpage:1370; lastpage:1385; numberofpages:16; journal:THE LANCET ONCOLOGY; http://hdl.handle.net/11586/327470Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85072673151

الإتاحة: https://doi.org/10.1016/S1470-2045Test(19)30413-9
http://hdl.handle.net/11586/327470Test

View record in BASE